Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday reported promising results from its Phase 2/3 COVA study of oral BIO101 (20-hydroxyecdysone) in the treatment of severe COVID-19 in hospitalised adults.
The findings were presented at the World Congress on Infectious Diseases in Paris, France.
Biophytis reported a statistically significant 43.8% reduction in the risk of early respiratory failure or death, along with a 44.6% reduction in the 90-day death rate. These positive findings come amid rising COVID-19 cases.
Seegene Inc developing fully automated PCR solution
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Kenox Pharmaceuticals partners with Lactiga US
Nona Biosciences signs licensing agreement with University of Alabama at Birmingham
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies